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SAT1Prostaglandins exert their effects on target cells by coupling to speciﬁc G protein-coupled receptors (GPCRs)
that are often co-expressed in the same cells and use alternate and in some cases opposing intracellular
signaling pathways. This study investigated the cross-talk that inﬂuences intracellular signaling and gene
expression proﬁling in response to co-activation of the EP2 and FP prostanoid receptors in Ishikawa cells
stably expressing both receptors (FPEP2 cells). In this study we show that in FPEP2 cells, PGF alone does not
alter adenosine 3′,5′-cyclic monophosphate (cAMP) production, but in combination with Butaprost enhances
EP2 receptor mediated cAMP release compared to treatment with Butaprost alone. PGF-mediated
potentiation of cAMP release was abolished by antagonism of the FP receptor, inhibition of phospholipase
C (PLC) and inositol phosphate receptor (IP3R) whereas inhibition of protein kinase C (PKC) had no effect.
Moreover, inhibition of calcium effectors using calmodulin antagonist (W7) or Ca2+/calmodulin-dependent
kinase II (CaMK-II) inhibitor (KN-93) abolished PGF potentiation of Butaprost-mediated cAMP release. Using
siRNA molecules targeted against the adenylyl cyclase 3 (AC3) isoform, we show that AC3 is responsible for
the cross-talk between the FP and EP2 receptors. Using gene array studies we have identiﬁed a candidate
gene, Spermidine/N1-acetyltransferase (SAT1), which is regulated by this cAMP mediated cross-talk. In
conclusion, this study demonstrates that co-activation of the FP and EP2 receptors results in enhanced
release of cAMP via FP receptor-Gαq-Ca2+-calmodulin pathway by activating calcium sensitive AC3 isoform.cco's modiﬁed eagle medium;
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Prostaglandins exert paracrine and autocrine effects on target
cells by coupling to their speciﬁc GPCRs and activate intracellular
signaling. PGE2 and PGF2α (PGF) are the most abundantly biosynthe-
sized prostaglandins and are major metabolites of cyclooxygenase
(COX) enzymes in the human endometrium [1,2]. Furthermore, COX
enzyme expression, prostaglandins synthesis and their cognate recep-
tors expression (mainly EP2 and FP) are dysregulated in endometrial
adenocarcinoma [3–5].EP2 and FP receptors are often co-expressed in the same cells and
use different intracellular signaling pathways. EP2 receptors couple to
Gαs, resulting in increased formation of cAMP,while FP receptors couple
to Gαq which in turn results in release of inositol-1,4,5-triphosphate
(IP) and dialcylglycerol (DAG) [1,6–8]. cAMP is generated in cells
from adenosine triphosphate (ATP) by the enzymatic activity of the
adenylyl cyclase (AC) family members. There are multiple AC isoforms
(9membrane-boundand1 soluble)withdifferent aminoacid sequence,
tissue distribution and regulation. AC isoforms are named from AC1 to
AC9 in the order of their publication [9,10]. Difference in regulation of
these isoforms includes sensitivity to calcium, G proteins (Gαi and Gβγ),
protein kinases (PKA, PKC, calmodulin and calmodulin-kinase) and
phosphatases (calcineurin). Out of the ten AC isoforms three (AC1, AC3
and AC8) are calcium stimulated while AC5 and AC6 are normally
inhibited by calcium in vivo [10,11]. The intracellular calcium pathway
has been shown to play a signiﬁcant part in Gαs–Gαq cross-talk by
regulating calcium sensitive AC isoforms [12–14]. For example, Ostrom
et al. [13] showed a potentiation of β-adrenergic (β-AR) receptor in-
duced cAMPproductionbyactivation of angiotensin II (ANG-II) receptor
coupled to Gαq protein through calcium/calmodulin pathway demon-
strating cross-talk between ANG-II and β-AR receptors in cardiac
ﬁbroblasts cells.
Table 1
Taqman primers and probes sequences for EP1, EP2, EP3, EP4, FP receptors, AC1, AC3,
SAT1 and 18S.
Target gene Primer and probe sequence (5′-3′)
EP1 receptor Forward primer AGATGGTGGGCCAGCTTGT
Reverse primer GCCACCAACACCAGCATTG
Probe (FAM) CAGCAGATGCACGACACCACCATG
EP2 receptor Forward primer GACCGCTTACCTGCAGCTGTA C
Reverse primer TGAAGTTGCAGGCGAGCA
Probe (FAM) CCACCCTGCTGCTGCTTCTCATTG TCT
EP3 receptor Forward primer GACGGCCATTCAGCTTATGG
Reverse primer TTGAAGATCATTTTCAACATCATTATCA
Probe (FAM) CTGTCGGTCTGCTGGTCTCCGCTC
EP4 receptor Forward primer ACGCCGCCTACTCCTACATG
Reverse primer AGAGGACGGTGGCGAGAAT
Probe (FAM) ACGCGGGCTTCAGCTCCTTCCT
FP receptor Forward primer GCAGCTGCGCTTCTTTCAA
Reverse primer CACTGTCATGAAGATTACTGAAAA AAATAC
Probe (FAM) CAC AAC CTG CCA GAC GGA AAA CCG
SAT1 Forward primer CGGGCCGACTGGTGTTTA
Reverse primer AGTCAGGCTGGCACCATGAC
Probe (FAM) CCGTCACTCGCCGAGGTTCCTTG
AC1 Forward primer TCTTCGGCAAGTTCGATGAA
Reverse primer GCAGTCCCCGAGAATCTTGA
Probe (FAM) TAGCCACGGAGAACCACTGTCGCC
AC3 Forward primer CTGATGTCACTGTAGCCAACAAGA
Reverse primer CCACATCAAACTCCCCTTTCA
Probe (FAM) CATCCCTGGGCGCGTGCAC
18S Forward primer CGGCTACCACATCCAAGGAA
Reverse primer GCTGGAATTACCGCGGCT
Probe (VIC) TGCTGGCACCAGACTTGCCCTC
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studies. Walsh and Kinsella [15] showed a cross-talk between throm-
boxane A2 (TPα and TPβ) and EP1 receptors in HEK 293 cells that
leads to desensitization and inhibition of signaling of the TP receptors
in a PKC-dependent manner. The same group further indentiﬁed that
the activation of the FP receptor by PGF can also mediate desensiti-
zation of the TPα and TPβ receptors via the PKC pathway [16]. In
another study, Wilson et al. [17] showed that heterodimerzation can
occur between the human receptors for prostacyclin (IP) and TPα
that leads to augmentation of TPα receptors-mediated accumulation
of cAMP by IP receptors when they are co-expressed in a HEK 293 cell
line.
Since EP2 and FP receptors are co-expressed in endometrial ade-
nocarcinoma cells [7,18], this study investigated the cross-talk that
may inﬂuence intracellular signaling and target gene activation in
response to co-activation of EP2 and FP receptors.
2. Materials and methods
2.1. Reagents
All chemicals used were molecular biology grade and were ob-
tained from Sigma (Dorset, UK or RSA) or IBI (Cambridge, UK). Cell
culture media was purchased from Gibco (Gibco, Paisely, UK). Hygro-
mycin (100 mg/ml stock) was purchased from Invitrogen (Invitrogen,
Autogen Bioclear UK) while G418 (100 mg/ml stock in PBS), in-
domethcin (3 mg/ml stock in ethanol), Butaprost (5 mM stock in
ethanol), PGF (100 µM stock in ethanol) and 3-isobutyl-1-methyl
xanthine (IBMX, 20 mM stock in 50% ethanol) were purchased from
Sigma (Sigma chemical Co., Nottingham, UK). FP receptor antagonist
(AL8810, 50 mM stock in ethanol), IP3R blocker (2-APB, 40 mM stock
in DMSO), PLC inhibitor (U73122, 10 mM stock in DMSO), calmodulin
antagonist (W7, 25 mM stock in DMSO), CaMK-II inhibitor (KN-93,
50 mM stock in DMSO) and PKC inhibitor (Ro-31-822, 1 mM stock in
DMSO) were all purchased from Calbiochem (Calbiochem, Notting-
ham, UK). Inhibitor of Gαq (YM254890, 1 mM stock in DMSO) was a
kind gift from M. Taniguchi, (Astellas Pharmaceuticals Inc., Tokyo,
Japan). The EP2 and FP receptor primary antibodies were purchased
from Cayman Chemical Company (Axxora, Nottingham, UK) and pri-
mary antibody for actin was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, Wiltshire, UK). Fluorescent secondary antibodies
were purchased from Li-Cor Biosciences (Li-Cor Biosciences, Cam-
bridge, UK). Stealth siRNA duplex oligoribonucleotides for AC1 and
AC3 were purchased from Invitrogen (Invitrogen, Paisley, UK).
2.2. Cell culture
Ishikawa cells were maintained as described previously [18].
FPEP2 clones were maintained in G418 and hygromycin (200 µg/ml
each) to select for the expression of FP and EP2 receptor, respectively.
2.3. EP2 receptor ampliﬁcation and stable cell line transfection
To make stable cell lines expressing both EP2 and FP receptors,
Ishikawa cells stably expressing the FP receptor (FPS32 cell lines)were
used as a parental cell line [7]. [6]. cDNA from proliferative endo-
metrium was synthesised as previously described [6] and EP2 recep-
tor was ampliﬁed using forward 5′-TCTCTTTTCCAGGCACCCCAC-3′
and reverse 5′-TTTTAAACTGACCTCAAAGGTCAGC-3′ primers. EP2 re-
ceptor cDNA was ligated into the pcDNA3.1 (Invitrogen) expression
vector in both sense and antisense directions and was transfected to
the FPS32 cells using SuperFect® transfection reagent (QIAGEN, UK)
according tomanufacturer's recommendations. Transfected cells were
selected in a medium containing 800 µg/ml of hygromycin in parallel
with untransfected cells. Once untransfected cells had died, hygro-
mycin-resistant clones were picked and expanded under the selectivemedium. Clones were then screened for the expression of the EP2
receptor by quantitative real-time RT-PCR and for their ability to pro-
duce intracellular cAMP in response to Butaprost treatment. Three
FPEP2 clones (clones 4, 8 and 10) with similar expression levels and
biochemical characteristics were selected for further investigation.
Data on FPEP2 clone 8 is presented here, with similar data obtained
using the other two clones.
2.4. cDNA synthesis and real-time RT-PCR
Total RNA was extracted from Ishikawa cells using Tri-Reagent
(Sigma-Aldrich Corp., Poole, UK) as manufacturer's recommendations
and cDNA was synthesised from total mRNA as described previously
[18]. Thereafter, quantitative real-time RT-PCR was performed with
speciﬁc E and F prostanoid (EP1, EP2, EP3, EP4 and FP receptors), AC1,
AC3 and SAT1 primers and probes (Table 1) as described previously
[18]. Expression of analyzed genes was normalized to RNA loading
for each sample using the 18S ribosomal RNA as an internal stan-
dard. Results are expressed as fold increase above vehicle treated
cells. Data are presented as mean±SEM from at least 3 independent
experiments.
2.5. Protein extraction from cells, SDS-PAGE and western blotting
Ishikawa cells were seeded at a density of 5×105 cells in 6 cm
dishes overnight. The following day protein was extracted from the
cells as described previously [18]. Total protein was quantiﬁed using
standard BIO-RAD DC assay (Bio-Rad, Hemel Hempstead, UK) as
directed by the manufacturer's instruction. A total of 40 μg of protein
was resuspended in 1× Laemmli buffer (125 mM Tris–HCL pH 6.8, 4%
SDS, 20% glycerol, 5% 2-mercapthoethanol and 0.05% bromophenol
blue) and boiled for 5 min at 95 °C. Samples were resolved and im-
munoblotted as described previously [18] prior to incubating with the
rabbit anti-EP2 or FP receptor in combination with goat anti-actin
primary antibody (all in 1:1000) at 4 °C overnight. The membrane
was then washed with PBS-Tween and incubated with the secondary
ﬂuorescence donkey anti-rabbit IgG conjugated to Alexa Fluor 680
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(Tebu-bio, Peterborough, UK) for 1h in the dark at 25 °C. After
washing the membrane proteins were then viewed using Odyssey
Infrared imaging system (Li-Cor Bioscience, Cambridge, UK).
2.6. Immunoﬂuorescence microscopy of cells
The site of EP2 and FP receptor expression in FPS32 and FPEP2
cells were localised using immunoﬂuorescence microscopy as de-
scribed previously [19]. Brieﬂy, 100,000 cells/well were plated out in
2-well cell chamber slides and left to adhere overnight. The next day
cells were ﬁxed with ice-cold 4% paraformaldehyde (PFA) for 20 min
and washed with PBS, before being blocked by 5% BSA diluted in
normal goat serum for 2 h. Thereafter, the cells were incubated with
polycolonal rabbit anti-EP2 and FP receptor antibody diluted in
normal goat serum (1:100) overnight at 4 °C. The next day, cells were
washed three times in PBS for 10 min and incubated with Alexa Flour
488 goat anti-rabbit IgG (1:200 in PBS; Molecular Probes) for 2 h.
Slides were counterstained with DAPI (1:1000 in PBS; Sigma) for
10 min for nuclear visualisation, washed and mounted in Permaﬂuor
(Immunotech-Coulter, Buckinghamshire, United Kingdom) and cov-Fig. 1. EP2 and FP receptor analysis in FPS32 and FPEP2 cells. Relative mRNA expression of (
time RT-PCR analysis in FPS32 and FPEP2 cells. Expression levels in FPEP2 clones are expresse
and EP2 receptors normalized for loading against ß-actin and expressed as fold increase abo
and EP2 (EP2R) receptor in FPS32 and FPEP2 cells as determined by immunoﬂuorescence m
speciﬁc blocking peptides. (E) The effect of 5 and 10 min treatments with vehicle or Butap
(n=4; **, P<0.001; ***, P<0.0001). (F) The effect of 60 min PGF stimulation on IP response
samples (n=5).erslipped for microscopic analysis. Control cells were incubated with
preadsorbed primary antibodies with a speciﬁc immunogen blocking
peptide.2.7. Ligand stimulation and cAMP assay
Butaprost and/or PGF-induced cAMP accumulation was deter-
mined by seeding 2×105 Ishikawa cells/well in 6-well plates. The cells
were serum-starved in the presence of 3 µg/ml of indomethacin (a
dual Cox enzyme inhibitor used to inhibit production of endogenous
prostaglandins). Thereafter, the cells were pre-treated with the
phosphodiesterase inhibitor IBMX (Sigma) to a ﬁnal concentration
of 0.2 mM in serum-free medium for 30 min. Cells were treated for
5 min with vehicle, Butaprost (5 µM) and/or PGF (100 nM) in the
presence/absence of different chemical inhibitors as described in the
ﬁgure legends. After incubation the cells were lysed in R&D Cell Lysis
Buffer™ (R&D Systems, Oxford UK) and cAMP release was determined
by ELISA using cAMP Kit (R&D Systems) according to manufacturer's
protocol. The concentration of cAMP was calculated using a standard
curve by Assay Zap (Biosoft, Cambridge, UK) and was normalizedA) EP2 receptor (B) EP1, EP3, EP4 and FP receptors as determined by quantitative real-
d as fold increase above FPS32 cells (n=4; ***, P<0.0001). (C) Protein expression of FP
ve FPS32 cells as determined by Western blot analysis. (D) Localization of the FP (FPR)
icroscopy. Control cells (C) were incubated with preadsorbed primary antibody using
rost on cAMP release in FPS32 and FPEP2 cells as determined by cAMP ELISA analysis
in FPS32 and FPEP2 cell lines. Data are expressed as fold increase above non-stimulated
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Data are represented as mean±SEM.
2.8. Total inositol phosphate (IP) assay
PGF and/or Butaprost-induced accumulation of IPwasdetermined as
previously described [20]. Brieﬂy, Ishikawa cells (50,000 cells/well)
were seeded in 24-well plates and allowed to adhere overnight. The
following day, cells were labeled with 0.5 µCi/well myo-3H-inositol
(Amersham Bioscineces, RSA) in an inositol-free DMEM 199 media
supplementedwith 2%dialyzed fetal calf serumovernight. The next day,
cells were stimulated with PGF and/or Butaprost with the required
concentration for an hour at 37 °C while non-stimulated samples were
taken as control for each experiment. After aspirating the buffer, cells
were lysed by the addition of 1 ml ice-cold 10 mM formic acid and the
plates were placed on ice for 30 min. Total 3H-inositol phosphates
were separated from cell extracts on AG 1-X8 resin by anion exchange
chromatography and counted by scintillation counting in Liquid Scin-
tillation Analyzer (Packard GmbH, Frankfurt, Germany). Data are re-
presented as mean±SEM and expressed as fold increase above non-
stimulated samples.
2.9. Knockdown of AC1 and AC3 with siRNA transfection
Three different Stealth siRNA duplex oligoribonucleotides (Invitro-
gen, Paisley, UK) were used to abolish the expression and function of
AC1 and AC3. FPEP2 Ishikawa cells were seeded (7.5×104 cells/well)
in complete media into 12-well plates. On the day of the transfection,
the cells were exposed to 60 nM (20 nM from each Stealth siRNA)
AC isoform-speciﬁc or scrambled sequence siRNA in the presence ofFig. 2. PGF enhances Butaprost-stimulated cAMP production via FP receptor-Gαq coupling and
(5 μM)Butaprost alone or PGF (10−10 to 10−6M)andButaprost (5 μM) together for 60 min as d
(n=4). (B) cAMP accumulation in FPEP2 cells after 5 min treatmentwith vehicle, Butaprost and
or PGF in the presence/absence of the EP2 receptor antagonist (AH6809), FP receptor antagonist
vehicle Butaprost and/or PGF or Butaprost and/or PGF together with the PLC inhibitor (10 µMU
**, P<0.001).SuperFect® (QIAGEN, Crawley, UK) for 6 h. After 48 h of transfection
the cells were subjected to RNA extraction for AC1 and AC3 mRNA
expression analysis or serum-starved overnight inmedium containing
indomethacin (3 µg/ml) for cAMP assay. For cAMP assay, cells were
then exposed to either Butaprost (5 µM) and/or PGF (100 nM) for
5 min, lysed and subjected to cAMP analysis as described earlier.
2.10. Gene array and data analysis
Ishikawa FPEP2 cellswere seeded at a density of 5×105 cells, serum-
starved for 18 h in the presence of 3 µg/ml of indomethacin. Cells were
then treated in serum-freemedia for 8 hwith vehicle, Butaprost (5 µM)
and/or PGF (100 nM). Treatments were performed in triplicate and
repeated four times, (total of n=12 for each treatment). After treat-
ment, the cells were washedwith ice-cold PBS, total RNAwas extracted
from each sample, RNA was analyzed and triplicates pooled to produce
four samples of each treatment for array analysis. RT-IVT was then
carried out in accordance to the Applied Biosystems Chemiluminescent
RT-IVT nanoamp (one-cycle) labelling protocol. Samples were frag-
mented andhybridized toAB1700version 2Applied BiosystemsHuman
Genome Survey microarrays. After hybridization the GeneChip arrays
were stained and washed on the ﬂuidics station and scanned. Data
acquired using ABI technology was pre-processed according to the
manufacturers' recommendations. The data was normalized using var-
iance stabilized normalization [21]. Normalized data were analyzed for
differential expression with the LIMMA package as described in the
LIMMA user guide [22]. The P values were adjusted for multiple testing
with Benjamini and Hochberg method [23]. The resulting gene list
included only the genes that had a fold change value of 2.0 or higher
and a P of <0.05. Bioinformatics was performed using the gene setPLC activation. (A) IP release in FPEP2 cells after treatmentwith PGF (10−10 to 10−6M) or
etermined by an IP assay. Data are expressed as fold increase above non-stimulated sample
/or PGF (n=4). (C) cAMP accumulation in FPEP2 cells treatedwith vehicle, Butaprost and/
(AL-8810) orGαq inhibitor (YM-254890) for 5 min (n=4). (D) cAMP in cells treatedwith
73122), IP3-R blocker (40 μm2-APB) or PKC inhibitor (1 μmRo-31-822) for 5 min (n=4;
Fig. 3. PGF potentiates Butaprost-stimulated cAMP through calmodulin-CaMK-II
pathway by activating AC3 isoform in FPEP2 cells. (A) cAMP accumulation in FPEP2
cells after 5 min treatment with vehicle, Butaprost and/or PGF in the presence/absence
of inhibitors for calmodulin (W7) or CaMK-II (KN-93) (n=4). (B) Real-Time RT-PCR
analysis of AC1 and AC3 in FPEP2 cells transfected with speciﬁc AC siRNA compared to
the control siRNA (scrambled sequence) (n=4). (C) cAMP accumulation in control,
AC1 or AC3 knockdown FPEP2 cells after 5 min treatment with vehicle, Butaprost and/
or PGF as determined by cAMP analysis (n=4; **, P<0.001).
75A.B. Abera et al. / Cellular Signalling 22 (2010) 71–79analysis tool kit [24]. A hypergeometric test was used to calculate
signiﬁcantly overrepresented ontologies from the gene list. Array
hybridization and data analysis was performed by GeneService Ltd
(Cambridge, UK). Gene Ontology annotations were assigned to classify
Butaprost and/or PGF regulated genes for biological processes and
molecular functions using a web tool provided by the gene ontology
database (www.geneontology.org).
2.11. Statistical analysis
All data are presented as mean±S.E.M. Statistical signiﬁcant dif-
ferenceswere determined by one-way analysis of variance using Prism
5.0 software (GraphPad Software Inc., San Diego, CA) (*, P<0.05;
**, P<0.001; ***, P<0.0001).
3. Results
3.1. EP2 and FP receptor expression in stably transfected Ishikawa cells
In order to investigate the cross-talk between the EP2 and FP
receptors, we created a stable cell line expressing the EP2 and FP
receptor in Ishikawa cells (FPEP2 cells). We initially assessed the
expression of the E prostanoid receptors (EP1, EP2, EP3 and EP4) and
FP receptor in FPEP2 cells in comparison with the parental FPS32
cells. As shown in Fig. 1A, quantitative real-time RT-PCR revealed a
signiﬁcant increase of EP2 receptor expression above the parental
FPS32 cells (P<0.0001). There was no signiﬁcant difference in ex-
pression of EP1, EP3, EP4 and the FP receptor between the FPEP2 cell
line and the parental FPS32 cell line (Fig. 1B). Western blot analysis
(Fig. 1C) and immunoﬂuorescence microscopy (Fig. 1D) conﬁrmed
elevated expression of EP2 receptor protein in the FPEP2 cells com-
pared to the FPS32 cells while the FP receptor expression was not
altered between the two cell lines.
Activation of the EP2 receptor by Butaprost leads to intracellular
accumulation of cAMP [25]. In order to assess the functionality of
the EP2 receptor in FPEP2 cells, the ability to generate cAMP was
determined by treating the cells with vehicle or Butaprost (5 μM) for
5 and 10 min. As shown in Fig. 1E, treatment of FPEP2 cells with
Butaprost for 5 or 10 min increased intracellular cAMP accumulation
signiﬁcantly (P<0.001 and P<0.0001, respectively) in a time-depen-
dent manner compared to vehicle treatment. Butaprost treatment of
the FPS32 cell line had no effect on intracellular cAMP accumulation
compared to vehicle treatment (Fig. 1E).
The FP receptor is a Gαq-coupled receptor, which upon PGF ac-
tivation leads to an accumulation of intracellular IP [25]. In order to
compare the functionality of the FP receptors in the parental FPS32
and FPEP2 cell lines, the cells were subjected to increasing doses of
PGF administration (10−10 to 10−6M) while control samples were
left untreated for an hour. As shown in Fig. 1F, PGF treatment of both
the parental FPS32 and FPEP2 cells gave a dose-dependent increase in
IP release with an Emax value of 15.7±0.6 and 16.6±2.1 and an EC50
value of 2.3 nM±0.3 and 1.95 nM±0.8 for the FPS32 and FPEP2 cell
lines respectively, conﬁrming our observations in Fig. 1B and C, that
the levels of FP receptor were similar between the FPS32 and FPEP2
cells.
3.2. PGF potentiates Butaprost-stimulated cAMP production via FP
receptor-Gαq coupling and PLC activation in FPEP2 Ishikawa cells
We next determined the integrated effect of Butaprost and PGF co-
administration on IP and cAMP release. FPEP2 cells were treated with
an increasing dose of PGF (10−10 to 10−6M) or 5 μM Butaprost alone
or with PGF (10−10 to 10−6M) and 5 μM of Butaprost together. As
shown in Fig. 2A, Butaprost treatment of the FPEP2 cells had no
effect on IP release, since treatment of PGF alone or in combination
with Butaprost gave a similar IP response (Emax 15.5±0.6 and Emax of16.6±2.2 and EC50 0.7 nM±0.5 and 1.95±1.04, respectively). These
data demonstrate that PGF-mediated IP release is not affected by
Butaprost treatment. To assess the effect of FP receptor induction by
PGF on Butaprost-stimulated cAMP accumulation, FPEP2 cells were
treatedwith vehicle, Butaprost (5 μM) and/or PGF (100 nM) for 5 min.
As shown in Fig. 2B, treatment of cells with Butaprost alone gave a
robust increase in intracellular cAMP accumulation compared with
vehicle treatment (P<0.001), while treatment with PGF alone had
minimal effect. However, co-treatment of the cells with Butaprost and
PGF together signiﬁcantly increased the cAMP response compared to
treatment with Butaprost alone (Fig. 2B; P<0.001).
To investigatewhether the augmentation of cAMP release by PGF is
mediated by either the EP2 or FP receptor, FPEP2 cells were treated
with Butaprost and/or PGF in the presence/absence of speciﬁc antag-
onist for the EP2 receptor (AH6809; 10 μm) or FP receptor (AL-8810;
50 μm). As shown in Fig. 2C, antagonism of the EP2 receptor sig-
niﬁcantly decreased (P<0.001) Butaprost-induced cAMP release in
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FP receptor antagonist only abolished the potentiation of cAMP by PGF
without altering basal and Butaprost-stimulated cAMP (P<0.001).
To assess if the PGF potentiation of Butaprost-stimulated cAMP
is mediated by FP receptor-Gαq coupling, FPEP2 cells were treated
with Gαq inhibitor (YM-254890; 1 μm) in the presence/absence of
Butaprost and/or PGF. As shown in Fig. 2C, the use of Gαq inhibitor
signiﬁcantly reduced the level of PGF and Butaprost-stimulated cAMP
to the level observed in the Butaprost-treated cells (P<0.001). These
data indicate that, PGF potentiation of Butaprost-stimulated cAMP
is mediated via the FP receptor activation of Gαq.
PGF activated FP receptor-Gαq coupling leads to activation of PLC
that results in both IP release, to increase intracellular calcium and
DAG release that activates PKC [7,26]. We assessed whether the PGF-
mediated enhancement of Butaprost-stimulated cAMP was via the
PLC-IP or PLC-PKC pathway. As shown in Fig. 2D, inhibition of PLC
using the PLCβ inhibitor U73122 (10 µM) abolished the augmentation
shown by PGF demonstrating this Gαs–Gαq cross-talk is mediated by
PLC activation. In order to determine whether intracellular calcium
or PKC activation mediate the observed cross-talk, the cells were
incubated with speciﬁc IP3R blocker (2-APB; 40 μm) or PKC inhibitor
(Ro-31-822; 1 μm) in the presence of Butaprost and/or PGF. Co-
treatment of the cells with 2-APB signiﬁcantly inhibited (P<0.001)
the PGF-mediated increase in Butaprost-induced cAMP release but
had no effect on Butaprost treatment alone.Whereas inhibition of PKC
had minimal effect on reducing the PGF-mediated augmentation of
cAMP demonstrating that PGF-mediated increase in cAMP is via the
accumulation of intracellular calcium (Fig. 2D).Table 2
Genes differentially expressed by Butaprost treatment only and modulated in combination
Gene
symbol
Gene name De
PGF enhanced modulation of gene expression
SAT1 Spermidine/spermine N1-acetyltransferase En
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 GT
FRAS1 Fraser syndrome 1 Ex
KCNK5 Potassium channel, subfamily K, member 5 Po
ATP1B3 Atpase, Na+/K+ transporting, beta 3 polypeptide Es
AQP3 Aquaporin 3 W
CDC42EP2 CDC42 effector protein 2 Ac
LIMS3 LIM and senescent cell antigen-like domains 3 Un
FAM100A Family with sequence similarity 100, member A Un
ZNF323 Zinc ﬁnger protein 323 Em
NR3C2 Nuclear receptor subfamily 3, group C, member 2 M
SPAG8 Sperm associated antigen 8 Tu
C10orf91 Chromosome 10 open reading frame 91 Un
DEFB1 Defensin, beta 1 An
KIAA1305 Kiaa1305 Un
ALDH3B2 Aldehyde dehydrogenase 3 family, member B2 De
RNF144B Ring ﬁnger protein 144B Re
SYNM Synemin In
MS4A2 Membrane-spanning 4-domains, subfamily A, mem 2 Su
RLN1 Relaxin 1 En
OR6W1P Olfactory receptor, family 6, subfamily W, member 1 pseudogene Ps
TRIM6 Tripartite motif-containing 6 An
SAMD13 Sterile alpha motif domain containing 13 Un
PGF repressed modulation of gene expression
CYP26A1 Cytochrome P450, family 26, subfamily A, polypeptide 1 Re
RPRM Reprimo, TP53 dependent G2 arrest mediator Po
IL1R2 Interleukin 1 receptor, type II Re
BTBD3 BTB (POZ) domain containing 3 Pr
ZNF703 Zinc ﬁnger protein 703 Re
ADA Adenosine deaminase Ca
C1orf168 Chromosome 1 open reading frame 168 Un
DDIT4 DNA-damage-inducible transcript 4 M
LIPC Lipase, hepatic Tr
VWA5A Von Willebrand factor A domain containing 5A Po
KCNJ5 Potassium channel, subfamily J, member 5 Po3.3. PGF-induced cAMP potentiation is mediated by intracellular Ca2+
transients and activation of the AC3 isoform in FPEP2 Ishikawa cells
Intracellular calcium is known to modulate calcium sensitive iso-
forms of AC to enhance cAMP production via activation of calmodulin-
CaMK-II pathway [27]. To determine whether the PGF-mediated
enhancement of cAMP is regulated by the calcium-calmodulin pathway,
chemical inhibitors against two calcium effectors were used. Inhibition
of calcium pathway, using calmodulin antagonist (W7; 25 μm) or
CaMK-II inhibitor (KN-93; 50 μm) signiﬁcantly reduced (P<0.001) the
level of cAMP release seen in FPEP2cells treatedwith the combinationof
Butaprost and PGF to Butaprost-stimulated level (Fig. 3A). These results
indicate that PGF potentiation of Butaprost-stimulated cAMP is by
the release of Ca2+ from intracellular stores leading to activation of
calmodulin-CaMK-II pathway.
To investigate which AC isoforms are present in FPEP2 cells, RT-PCR
was performed using AC isoform-speciﬁc primers. We found that
Ishikawa cells express mRNA for AC1, AC3, AC4, AC5, AC6, AC7, AC9
and the solubleAC(SAC), but not AC2orAC8 isoforms (data not shown).
Out of the eight isoforms expressed in Ishikawa cells two of them are
known to be calcium stimulated (AC1 and AC3) [11]. Calcium-regulated
AC isoforms have been suggested to be involved in Gαs–Gαq cross-talk
[12–14,28]. To identify which AC isoform is involved in the EP2-FP
receptor cross-talk, siRNA designed to AC1 and AC3 were used to
knockdown endogenous mRNA expression of the speciﬁc isoforms.
After speciﬁc siRNA transfection into FPEP2 cells, quantitative real-time
RT-PCR showed that AC1 and AC3 mRNA expressions were reduced by
76% and 70% respectively compared with scrambled sequence siRNAwith PGF treatment.
scription Mean fold change
Butaprost PGF and
Butaprost
zyme in the pathway of polyamine metabolism 5.94 7.47
Pase function in signal transduction 3.48 4.05
tracellular matrix protein, adhesion 3.46 6.41
tassium channel 3.20 3.71
tablishing and maintaining gradients of Na and K ions 3.19 4.28
ater channel protein 3.03 3.57
tin ﬁlament assembly and cell shape control 3.02 4.16
known 2.98 3.81
known 2.87 3.55
bryo development 0.16 0.12
ineralocorticoid receptor 0.18 0.14
mor progression 0.24 0.15
known 0.27 0.14
timicrobial peptide 0.32 0.29
known 0.32 0.23
toxiﬁcation of aldehydes 0.33 0.29
gulate the stability of p21 0.33 0.27
termediate ﬁlament protein 0.34 0.26
bunit of the high afﬁnity IgE receptor 0.34 0.29
docrine and autocrine/paracrine hormone 0.35 0.32
eudogene 0.35 0.29
tiretroviral 0.35 0.30
known 0.35 0.31
gulates the cellular level of retinoic acid 18.03 12.28
tential tumor suppressor 11.90 7.76
ceptor that inhibits the activity of its ligands 3.98 3.62
oliferation and anti-apoptosis 3.30 3.02
pressor of transcription 3.28 3.04
talyzes the hydrolysis of adenosine to inosine 3.15 2.87
known 0.23 0.31
ediator in RAS-mediated transformation 0.22 0.26
iglyceride hydrolase and factor for lipoprotein uptake 0.19 0.22
tential tumor suppressor 0.17 0.23
tassium channel 0.16 0.22
Fig. 4. PGF potentiates Butaprost-regulated SAT1 gene expression in FPEP2 cells via the
calcium sensitive AC3 isoform. (A) Relative expression of SAT1 in FPEP2 cells after 4, 6
and 8 h treatments with vehicle, Butaprost and/or PGF (n=4). (B) Relative expression
of SAT1 in FPEP2 cells after 6 h treatment with vehicle, Butaprost and/or PGF in the
absence or presence of the FP receptor antagonist (AL8810) (n=4). (C) Relative
expression of SAT1 in FPEP2 cells transfected with siRNA and subsequently treated for
6 h with vehicle, Butaprost and/or PGF (n=4); (**, P<0.001).
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both AC1 and AC3 siRNA inhibited the expression of their cognate
targets without altering the other (Fig. 3B). After 48 h of siRNA trans-
fection, cells were exposed to either Butaprost and/or PGF for 5 min.
Thereafter, cells were lysed and subjected to cAMP analysis as described
earlier to assess the functional effect of the knockdown. As shown
in Fig. 3C, transfection with AC3 siRNA completely abolished the
potentiation of Butaprost-stimulated cAMP by PGF signiﬁcantly
(P<0.001) while AC1 siRNA transfection had no effect on cAMP ac-
cumulation. This result demonstrates that PGF can enhance Butaprost-
stimulated cAMPvia the FP receptor-Gαq-Ca2+-calmodulin pathway by
activating the calcium sensitive AC3 isoform.
3.4. Gene array analysis
Gene array analysis was used to identify downstream gene
transcriptional changes inﬂuenced by PGF-enhanced Butaprost-stimu-
lated cAMP signaling. Ishikawa FPEP2 cells were treated with vehicle,
Butaprost and/or PGF for 8 h. RNAwas extracted, hybridized to AB1700
gene chips, and subjected to gene array analysis. The analysis identiﬁed
34 genes whose expression was not regulated by PGF alone, but altered
in response to Butaprost and PGF co-treatment compared to treatment
with Butaprost alone (Table 2). For example SAT1 gene expression
was enhanced from a 5.9 fold increase to a 7.5 fold increase, whereas
cytochrome P450, family 26, subfamily A, polypeptide 1 (CYP26A1)
gene expression was repressed from an 18.0 fold increase to a 12.3 fold
increase. To determine whether the list contained genes with common
functions the Gene Ontology database was used to group the genes into
functional ontologies. Three functional groups were identiﬁed which
were represented by 5 or more genes, those for cellular metabolism,
immune response and excretion.
3.5. Butaprost-mediated SAT1 gene expression is potentiated by Gαs–Gαq
cross-talk
Since our array analysis has demonstrated a unique subset of genes,
whose expression induced by Butaprost was modulated by PGF, we
next investigated the integrated Gαs–Gαq cross-talk regulating down-
stream transcriptional activation by analyzing a candidate gene SAT1,
selected from the gene list (Table 2). We focused on the regulation
of this gene since it is known to be regulated by cAMP via the cAMP
response element binding protein (CREB) that is located on its pro-
moter region [34]. To study the temporal expression of this gene,
FPEP2 Ishikawa cells were treated with vehicle, Butaprost and/or PGF
for 4, 6 and 8 h. As shown in Fig. 4A, Butaprost treatment alone
signiﬁcantly increased expression of SAT1 at all time points com-
pared to vehicle treatment (P<0.001). No signiﬁcant elevation of
SAT1 gene expression was observed following PGF treatment alone.
However, co-stimulation of FPEP2 cells with Butaprost and PGF en-
hanced the Butaprost-stimulated expression of SAT1 signiﬁcantly at
all time points (P<0.001). To determine whether the PGF-mediated
potentiation of SAT1 expression is mediated by the FP receptor, the
cells were treated with the FP receptor antagonist (AL8810) in the
presence/absence of Butaprost and/or PGF for 6 h. As shown in Fig. 4B,
antagonism of the FP receptor completely abolished the potentiation
of SAT1 expression by PGF without altering Butaprost-stimulated
expression of SAT1. These data demonstrate that Butaprost-regulated
expression of SAT1 is augmented by PGF-FP receptor coupling.
Since we have shown that AC3 is involved in the Gαs–Gαq cross-
talk in FPEP2 cells, we assessed if the same isoform is involved in
PGF-mediated potentiation of SAT1 expression. As shown in Fig. 4C,
ablation of AC3 expression reduced SAT1 mRNA expression in FPEP2
cells treated with the combination of Butaprost and PGF to the level
observed following stimulation with Butaprost alone (P<0.001).
These data demonstrate that PGF-mediated potentiation of SAT1mRNA expression is mediated by the EP2-FP receptor cross-talk via
the FP receptor activation of the calcium sensitive AC3 isoform.
4. Discussion
There is mounting evidence to support a role for prostaglandins
and their respective receptors in endometrial pathologies such as
dysmenorrhoea, endometriosis, menorrhagia and endometrial ade-
nocarcinoma [3,5,29,30]. Studies in our laboratory and others have
used a reductionist approach to dissecting the signaling pathways
following the activation of individual EP2 or FP receptors in numerous
cell types. We have shown activation of the EP2 and FP receptors can
lead to phosphorylation of ERK1/2 via the activation of c-Src and
transphosphorylation of the epidermal growth factor receptor (EGFR)
in Ishikawa cells and endometrial adenocarcinoma explants ex vivo
[7,18]. In addition others have shown activation of the EP2 receptors
can trigger the Wnt signaling pathway that involves phosphorylation
of glycogen synthase kinase-3 (GSK-3) by Akt to activate β-catenin
mediated transcriptional activation in HEK 293 cells [31].
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This suggests that co-activation of prostanoid receptors in the same
cell could alter the physiological/pathophysiological gene expression
proﬁle and outcome. However, to our knowledge there have been no
studies addressing the integrative signaling effects of the EP2 and
FP receptors on signal transduction and gene expression. Here we
show for the ﬁrst time that co-activation of prostanoid receptors can
alter the gene expression proﬁle in endometrial adenocarcinoma cells
stably expressing the EP2 and FP receptors. In addition to our knowl-
edge this is the ﬁrst study to investigate the cross-talk between the
EP2 and FP receptors and the molecular mechanism underlying the
intracellular signaling pathway in response to co-activation of both
receptors.
In order to investigate prostanoid integrative signaling, we stably
transfected the EP2 receptor into Ishikawa cells stably expressing the
FP receptor. Expression level of the EP2 receptor in FPEP2 cells was
compared to the parental FPS32 cells using quantitative real-time RT-
PCR, Western blot analysis and immunoﬂuorescence microscopy
conﬁrming stable expression of EP2 receptor in FPEP2 cells localised
to the perinuclear and plasma membrane. Introduction of the EP2
receptor had no effect on the expression proﬁle of the other E-series
receptors and of FP receptor which could be activated by prostanoid
ligands in our study. Furthermore, the functionality of EP2 and FP
receptors was also conﬁrmed by the release of their respective sec-
ondary messengers, cAMP and IP in the presence of their respective
ligands.
Using the FPEP2 cells as a model system, we showed that Butaprost
stimulation of FPEP2 cells gave a robust intracellular accumulation
of cAMP while PGF-mediated FP receptor activation by its own had
no effect on cAMP production. Interestingly we found that PGF could
signiﬁcantly enhance the cAMP accumulation in combination with
Butaprost. Using speciﬁc receptor antagonists and small molecule
chemical inhibitors of cell signalingwedissected the signalingpathways
mediating the PGF-induced augmentation of cAMP in cells treated with
the combination of ligands and have shown that the PGF-enhancementFig. 5. Gαq-mediated potentiation of Butaprost-induced cAMP release. Butaprost activa
accumulation while PGF by itself does not alter cAMP production. However, co-treatment of t
from the plasma membrane. Subsequently, IP3 via the IP3 receptor (IP3R) mediates the
potentiation of cAMP release via the calcium sensitive AC3 isoform and modulation of geneof cAMP observed in FPEP2 cells treated with Butaprost and PGF was
induced via the FP receptor-Gαq-mediated activation of IP via PLC.
Following its release IP could activate its receptors (IPR) present on
the endoplasmic reticulum (ER) membrane to promote intracellular
calcium release and activation of calmodulin and CaMK-II as depicted
schematically in Fig. 5. Numerous studies have shown that the CaMK-II
pathway can activate calcium sensitive AC isoforms to regulate
intracellular cAMP accumulation [12–14,27,28]. We identiﬁed AC1
and AC3 as calcium-regulated targets in our FPEP2 cells by RT-PCR
analysis. Transfection studies using siRNA to abolish expression of AC1
or AC3 in FPEP2 cells revealed that the calcium sensitive AC3 (but not
AC1) isoform is responsible for PGF-mediatedpotentiation of Butaprost-
stimulated cAMP. These data suggest that the cAMPmediated Gαs–Gαq
cross-talk reported here is via the activation of the calcium sensitive
isoform AC3.
There has been other cAMP mediated Gαs–Gαq cross-talk reported
but only onewith physiological relevance [12–14]. The Gαs–Gαq cross-
talk reported by Ostram et al. [13] had an important physiological
consequence on regulation of the extracellular matrix in myocardium.
The authors showed β-adrenergic receptor mediated inhibition of col-
lagen synthesis was further decreased by co-activation of angiotensin II
receptor suggesting the cross-talk might play a role in inhibition of
ﬁbrosis in heart. In order to determine the integrative effects of receptor
co-activation on gene expression, we performed whole genome array
proﬁling in FPEP2 cells in response to Butaprost, PGF or the combination
of Butaprost and PGF. Co-activation of FPEP2 cells with Butaprost and
PGF enhanced or repressed a set of Butaprost (EP2 receptor) regulated
genes. Analysis of the gene list for Gene Ontology annotations indicated
functions in cellular metabolism, immune response and excretion. One
of the genes identiﬁed, SAT1 is an important enzyme in polyamine
metabolism, adding an acetyl group to aminopropyl ends of spermidine
and spermine [33]. The promoter region of SAT1 lacks TATA box but
has multiple binding sites for transcriptional factors including CREB,
suggesting it is cAMP regulated [34]. We investigated the integrative
signalingmediating the role of prostanoids on SAT1 expression in FPEP2tes Gαs-coupled EP2 receptors resulting in a rapid increase in intracellular cAMP
he cells with both ligands leads to the Gαq-mediated activation of PLC and release of IP3
release of Ca2+ from intracellular stores leading to calmodulin-CaMK-II dependent
transcription such as SAT1.
79A.B. Abera et al. / Cellular Signalling 22 (2010) 71–79cells. We found that SAT1 is regulated by the cAMPmediated Gαs–Gαq
cross-talk via AC3, such that siRNA knockdown of the AC3 isoform
completely inhibited the potentiation of Butaprost-stimulated SAT1
expression by PGF. SAT1 is a highly regulated enzyme and it is inducible
by polyamines and has been shown to be involved in carcinogenesis
[35]. A transgenic increase of SAT1 expression inmice showed a variety
of defects such as hair loss, female infertility, impaired lipidmetabolism
and predisposition to develop pancreatitis [36]. Tucker et al. [37]
showed SAT1-over producing transgenic mice bred with Apcmin/+ mice
(mice predisposed to intestinal tumor formation) had an increase in
incidence of intestinal tumors while crosses with SAT1 knockout mice
led to 75% reduction in tumor load.
Although the role of SAT1 in endometrial pathologies with dys-
regulated prostanoids is unclear, SAT1 has been shown to have a direct
effect on cell migration by bindingwithα9B1-integrin [38]. Moreover,
in a recent study, Vlahakis et al. [39] have demonstrated that α9B1-
integrin can bind to the vascular endothelial growth factor (VEGF) to
promote angiogenesis. In light of these studies, SAT1 might play a role
in pathologies of endometrium by directly promoting cell migration
and an indirect enhancement of angiogenesis via α9B1-integrin.
5. Conclusions
This study demonstrates that co-activation of the EP2 and FP
receptors results in enhanced release of cAMP, in a Gαq-calcium-
dependentmanner via the calcium sensitive AC3 isoform. Activation of
this pathway modulates expression of genes involved in metabolism,
immune response and excretion. Taken together our data suggest that
when both EP2 and FP receptors are co-activated this leads to a unique
integrative signaling pathway that modulates downstream gene ex-
pression of a subset of EP2 receptor induced genes.
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